Reference:
1. Kang, S., et al., Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment. Int J Antimicrob Agents, 2020.55 (5): p. 105950.
2. WHO. WHO Coronavirus (COVID-19) Dashboard . 2023; Available from: https://covid19.who.int/.
3. Polatoğlu, I., et al., COVID-19 in early 2023: Structure, replication mechanism, variants of SARS-CoV-2, diagnostic tests, and vaccine & drug development studies. MedComm (2020), 2023.4 (2): p. e228.
4. Agbuduwe, C. and S. Basu, Haematological manifestations of COVID-19: From cytopenia to coagulopathy. Eur J Haematol, 2020.105 (5): p. 540-546.
5. Castiello, T., et al., COVID-19 and myocarditis: a systematic review and overview of current challenges. Heart Fail Rev, 2022.27 (1): p. 251-261.
6. Erdinc, B., S. Sahni, and V. Gotlieb, Hematological manifestations and complications of COVID-19. Adv Clin Exp Med, 2021.30 (1): p. 101-107.
7. Myall, K.J., et al., Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. Ann Am Thorac Soc, 2021. 18 (5): p. 799-806.
8. Sawalha, K., et al., Systematic Review of COVID-19 Related Myocarditis: Insights on Management and Outcome. Cardiovasc Revasc Med, 2021. 23 : p. 107-113.
9. Taha, S.I., et al., Post-COVID-19 arthritis: is it hyperinflammation or autoimmunity? Eur Cytokine Netw, 2021.32 (4): p. 83-88.
10. Tang, K.T., B.C. Hsu, and D.Y. Chen, Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review. Front Immunol, 2021. 12 : p. 645013.
11. Valenzuela, C., G. Waterer, and G. Raghu, Interstitial lung disease before and after COVID-19: a double threat? Eur Respir J, 2021.58 (6).
12. Cruz-Jentoft, A.J. and A.A. Sayer, Sarcopenia. Lancet, 2019.393 (10191): p. 2636-2646.
13. Dhillon, R.J. and S. Hasni, Pathogenesis and Management of Sarcopenia. Clin Geriatr Med, 2017. 33 (1): p. 17-26.
14. Sieber, C.C., Malnutrition and sarcopenia. Aging Clin Exp Res, 2019. 31 (6): p. 793-798.
15. Papadopoulou, S.K., Sarcopenia: A Contemporary Health Problem among Older Adult Populations. Nutrients, 2020. 12 (5).
16. Stuck, A.K., et al., Comparing Prevalence of Sarcopenia Using Twelve Sarcopenia Definitions in a Large Multinational European Population of Community-Dwelling Older Adults. J Nutr Health Aging, 2023. 27 (3): p. 205-212.
17. Cruz-Jentoft, A.J., et al., Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing, 2019.48 (1): p. 16-31.
18. Siahaan, Y.M.T., et al., Coronavirus disease 2019 (Covid-19) outcomes in patients with sarcopenia: A meta-analysis and meta-regression. Clin Nutr ESPEN, 2022. 48 : p. 158-166.
19. Xu, Y., et al., Prevalence of Sarcopenia in Patients With COVID-19: A Systematic Review and Meta-Analysis. Front Nutr, 2022.9 : p. 925606.
20. Yamamoto, S., et al., Clinical Outcomes and Prevalence of Sarcopenia in Patients with Moderate to Severe COVID-19. J Clin Med, 2022. 11 (21).
21. Levy, D., et al., Long Term Follow-Up of Sarcopenia and Malnutrition after Hospitalization for COVID-19 in Conventional or Intensive Care Units. Nutrients, 2022. 14 (4).
22. González-Islas, D., et al., Body composition and risk factors associated with sarcopenia in post-COVID patients after moderate or severe COVID-19 infections. BMC Pulm Med, 2022. 22 (1): p. 223.
23. Piotrowicz, K., et al., Factors associated with mortality in hospitalised, non-severe, older COVID-19 patients - the role of sarcopenia and frailty assessment. BMC Geriatr, 2022. 22 (1): p. 941.
24. Riesgo, H., et al., Prevalence of Risk of Malnutrition and Risk of Sarcopenia in a Reference Hospital for COVID-19: Relationship with Mortality. Ann Nutr Metab, 2021. 77 (6): p. 324-329.
25. Sekula, P., et al., Mendelian Randomization as an Approach to Assess Causality Using Observational Data. J Am Soc Nephrol, 2016.27 (11): p. 3253-3265.
26. Zabor, E.C., A.M. Kaizer, and B.P. Hobbs, Randomized Controlled Trials. Chest, 2020. 158 (1s): p. S79-s87.
27. Bowden, J. and M.V. Holmes, Meta-analysis and Mendelian randomization: A review. Res Synth Methods, 2019. 10 (4): p. 486-496.
28. Davey Smith, G. and G. Hemani, Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet, 2014. 23 (R1): p. R89-98.
29. IEU. IEU OpenGWAS Project . 2023; Available from:https://gwas.mrcieu.ac.uk/.
30. Timmins, I.R., et al., Genome-wide association study of self-reported walking pace suggests beneficial effects of brisk walking on health and survival. Commun Biol, 2020. 3 (1): p. 634.
31. COVID19-hg. COVID19-hg GWAS meta-analyses round 5 . 2023; Available from:https://www.covid19hg.org/results/.
32. Bowden, J., G. Davey Smith, and S. Burgess, Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol, 2015.44 (2): p. 512-25.
33. Verbanck, M., et al., Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet, 2018. 50 (5): p. 693-698.
34. Greco, M.F., et al., Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med, 2015. 34 (21): p. 2926-40.
35. Ranstam, J., Multiple P-values and Bonferroni correction.Osteoarthritis Cartilage, 2016. 24 (5): p. 763-4.
36. Sedgwick, P., Multiple hypothesis testing and Bonferroni’s correction. Bmj, 2014. 349 : p. g6284.
37. Jimeno-Almazán, A., et al., Post-COVID-19 Syndrome and the Potential Benefits of Exercise. Int J Environ Res Public Health, 2021.18 (10).
38. Piotrowicz, K., et al., Post-COVID-19 acute sarcopenia: physiopathology and management. Aging Clin Exp Res, 2021.33 (10): p. 2887-2898.
39. Mohamadian, M., et al., COVID-19: Virology, biology and novel laboratory diagnosis. J Gene Med, 2021. 23 (2): p. e3303.
40. Wade, F.E., et al., Kinematic analysis of speed transitions within walking in younger and older adults. J Biomech, 2022.138 : p. 111130.
41. Wu, T. and Y. Zhao, Associations between functional fitness and walking speed in older adults. Geriatr Nurs, 2021. 42 (2): p. 540-543.
42. Colleluori, G. and D.T. Villareal, Aging, obesity, sarcopenia and the effect of diet and exercise intervention. Exp Gerontol, 2021.155 : p. 111561.
43. Sattar, N., I.B. McInnes, and J.J.V. McMurray, Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. Circulation, 2020. 142 (1): p. 4-6.
44. Mapping the human genetic architecture of COVID-19. Nature, 2021. 600 (7889): p. 472-477.
45. Gao, M., et al., Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol, 2021.9 (6): p. 350-359.
46. De Lorenzo, A., et al., Fat mass affects nutritional status of ICU COVID-19 patients. J Transl Med, 2020. 18 (1): p. 299.
47. Manolis, A.S., et al., COVID-19 infection and body weight: A deleterious liaison in a J-curve relationship. Obes Res Clin Pract, 2021. 15 (6): p. 523-535.
48. Watanabe, M., et al., Obesity and SARS-CoV-2: A population to safeguard. Diabetes Metab Res Rev, 2020: p. e3325.
49. Gil, S., et al., Muscle strength and muscle mass as predictors of hospital length of stay in patients with moderate to severe COVID-19: a prospective observational study. J Cachexia Sarcopenia Muscle, 2021.12 (6): p. 1871-1878.
50. Sevilla, G.G.P. and B. Sánchez-Pinto, Associations between muscle strength, dyspnea and quality of life in post-COVID-19 patients.Rev Assoc Med Bras (1992), 2022. 68 (12): p. 1753-1758.
51. Kara, Ö., et al., Grip strength as a predictor of disease severity in hospitalized COVID-19 patients. Heart Lung, 2021.50 (6): p. 743-747.
52. Piotrowicz, K. and J. Gąsowski, Risk Factors for Frailty and Cardiovascular Diseases: Are They the Same? Adv Exp Med Biol, 2020.1216 : p. 39-50.
53. Franceschi, C., et al., Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol, 2018.14 (10): p. 576-590.